This proposal would be in line with a recent report, where the PDI inhibitor PACMA 31 significantly suppressed ovarian tumor growth while it was substantially less toxic to normal tissue.24 Certainly, it would be informative to test whether PACMA31-mediated inhibition of PDI influences PERK signaling in these authors’ model. This evidence concerns the gene EIF2AK3 and ovarian neoplasm.